

*See, e.g.*, Tim Wilsdon, Jim Attridge, Eva Fiz, & Satomi Ginoza, *Policies that Encourage Innovation in Middle-Income Countries* 8 (Oct. 2012), [https://www.ifpma.org/wp-content/uploads/2012/01/CRA\\_Policies](https://www.ifpma.org/wp-content/uploads/2012/01/CRA_Policies) (“[T]he great majority of international R&D sites continue to be in the US and Europe, but the importance of China has increased dramatically . . ..”);

Preetika Rana, *Your Cancer Drugs May Soon Be Discovered in China*, Wall Street Journal (Apr. 11, 2017), <https://www.wsj.com/articles/china-emerges-as-powerhouse-for-biotech-drugs-1491816607> (observing that biotech R&D investment has shifted to China, due to the inability of U.S. companies to obtain patents);

Jack Ellis, *China Relaxes Rules on Software Patentability – and the United States Loses More Ground*, IAM (Mar. 3, 2017), <https://www.iam-media.com/law-policy/china-relaxes-rules-software-patentability-and-united-states-loses-more-ground> (“China’s apparent embrace of software patents stands in stark contrast to the situation in the United States, which many would see as the traditional home of the software industry.”).